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Longitudinal investigation of DNA
methylation changes preceding adolescent
psychotic experiences
Susanna Roberts1, Matthew Suderman2, Stanley Zammit3,4, Sarah H. Watkins3, Eilis Hannon 5, Jonathan Mill 5,
Caroline Relton2, Louise Arseneault1, Chloe C. Y. Wong1 and Helen L. Fisher 1
Abstract
Childhood psychotic experiences (PEs), such as seeing or hearing things that others do not, or extreme paranoia, are
relatively common with around 1 in 20 children reporting them at age 12. Childhood PEs are often distressing and can
be predictive of schizophrenia, other psychiatric disorders, and suicide attempts in adulthood, particularly if they
persist during adolescence. Previous research has demonstrated that methylomic signatures in blood could be
potential biomarkers of psychotic phenomena. This study explores the association between DNA methylation (DNAm)
and the emergence, persistence, and remission of PEs in childhood and adolescence. DNAm profiles were obtained
from the ALSPAC cohort at birth, age 7, and age 15/17 (n= 901). PEs were assessed through interviews with
participants at ages 12 and 18. We identified PE-associated probes (p < 5 × 10−5) and regions (corrected p < 0.05) at
ages 12 and 18. Several of the differentially methylated probes were also associated with the continuity of PEs across
adolescence. One probe (cg16459265), detected consistently at multiple timepoints in the study sample, was
replicated in an independent sample of twins (n= 1658). Six regions, including those spanning the HLA-DBP2 and
GDF7 genes, were consistently differentially methylated at ages 7 and 15–17. Findings from this large, population-
based study suggest that DNAm at multiple stages of development may be associated with PEs in late childhood and
adolescence, though further replication is required. Research uncovering biomarkers associated with pre-clinical PEs is
important as it has the potential to facilitate early identification of individuals at increased risk who could benefit from
preventive interventions.
Introduction
Psychotic experiences (PEs), such as hearing voices,
seeing visions, or being extremely paranoid, are experi-
enced by around 1 in 20 children1, usually without a
diagnosable illness. In most children these experiences
remit, but nonetheless they are associated with later
psychiatric problems such as psychotic disorders2,
including schizophrenia3,4, and post-traumatic stress
disorder3, as well as suicidality and self-harm in adoles-
cence1,5, and suicide attempts in adulthood3. The like-
lihood of developing a psychotic disorder6 or post-
traumatic stress disorder7 is especially increased if PEs
persist during adolescence. Therefore, it is important to
identify as early as possible which children are at risk of
developing these experiences. Uncovering biomarkers
associated with the onset and persistence of pre-clinical
PEs in childhood can increase our understanding of the
aetiological factors accompanying the development and
progression of PEs, and may in the future facilitate early
identification of individuals at increased psychiatric risk,
and improve targeting of preventive interventions.
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Biomarkers for the emergence and persistence of PEs
might be evident at the level of epigenetics, that is by any
of the many cellular mechanisms capable of regulating
gene expression without changes in the underlying
genetic sequence. DNA methylation (DNAm) patterns
have, for example, been associated with a broad range of
psychiatric phenotypes8–14, including schizophrenia and
other psychotic disorders. Research in monozygotic twin
pairs discordant for a clinical diagnosis of psychosis15 and
in case–control samples16–22 has identified DNAm dif-
ferences associated with psychosis. Importantly, these
findings were identified not only in post-mortem brain
tissue from diagnosed individuals19,21,22, but also in per-
ipheral samples from living patients15–18,20, and studies
have replicated findings from peripheral samples in post-
mortem tissue15.
To date, the majority of studies have relied on cross-
sectional analyses of DNAm and psychotic disorder sta-
tus. Cross-sectional studies with affected individuals are
likely to be highly confounded by factors associated with
the disorder, such as medication. Crucially, few epigenetic
studies have utilised prospective designs to focus on pre-
clinical psychotic phenomena in the general population,
which are important to optimise early detection efforts.
To this end, research from our group recently demon-
strated specific DNAm differences at age 10 between
monozygotic twin pairs discordant for psychotic symp-
toms at age 12 (n= 48;23). Of note, hypomethylation of
the top-ranked CpG site was replicated in post-mortem
brain tissue in an independent sample of schizophrenia
patients compared to controls, and several of the findings
of interest were located in, or near, genes previously
implicated in neurodevelopment and psychiatric dis-
orders. Furthermore, a recent study found that conversion
to psychosis in young help-seeking individuals (an ultra-
high risk group, n= 39) was associated with differential
changes in DNAm, with top results occurring in pathways
relevant for psychosis such as oxidative stress regulation,
axon guidance and inflammatory pathways24. These stu-
dies indicate that the PEs in pre-diagnosis populations
may be associated with differential DNAm, and that the
pattern of PEs may correspond with changes in DNAm in
relevant pathways. However, it is difficult to draw firm
conclusions based on such small samples that may not be
representative of the broader population.
The aim of this study was to explore associations
between genome-wide DNAm patterns and the emer-
gence and persistence of PEs in childhood and adoles-
cence utilising a longitudinal design covering key points in
development in a large, population-based sample. First,
we investigated the association between DNAm at specific
timepoints during childhood and adolescence (birth, age
7, and age 15–17) and reports of PEs at ages 12 and 18.
Second, we examined the role of DNAm in the continuity
of PEs by comparing individuals whose experiences per-
sisted between 12 and 18 years with those whose
experiences remitted, emerged for the first time during
adolescence, and those with no history of such experi-
ences. Third, we explored the association between long-
itudinal trajectories of DNAm and PEs across early
development. Fourth, we investigated differentially
methylated regions (DMRs) associated with PEs. Finally,
we tested the robustness of these findings in an inde-
pendent sample.
Methods
Sample
The Avon Longitudinal Study of Parents and Children
(ALSPAC) is a large, prospective cohort study that
recruited 14,541 pregnant women resident in Avon, UK
with expected dates of delivery between 1 April 1991 and
31 December 199225,26. Further details of the study and
available data are provided on the study website through a
fully searchable data dictionary (http://www.bris.ac.uk/
alspac/researchers/data-access/data-dictionary/). The
current study focusses on the Accessible Resource for
Integrated Epigenomic Studies (ARIES) sub-study, which
consists of 1018 mother–offspring pairs who provided
DNA samples at multiple timepoints27. All data are
available by request from the Avon Longitudinal Study of
Parents and Children Executive Committee (http://www.
bristol.ac.uk/alspac/researchers/access/) for researchers
who meet the criteria for access to confidential data.
Written informed consent was provided by parents and
assent by children during the childhood phases of the
study, and then by the children themselves at age 18.
Ethical approval for the study was obtained from the
ALSPAC Law and Ethics Committee and the Local
Research Ethics Committees. Ethical approvals are in
place for all sources of biological samples and data in
ARIES in accordance with the Declaration of Helsinki.
Measures
Psychotic experiences
PEs at ages 12 and 18 were assessed via semi-structured
interviews (Psychosis-like symptoms semi-structured
interview—PLIKSi) that have been described pre-
viously2,28. At 12 years participants were asked about PEs
over the previous 6 months; at 18 years participants were
asked about experiences since the age of 12. Further
details regarding determination of PEs in this sample are
provided in the Supplementary Information. For long-
itudinal analyses, individuals were included if they had PE
data available at both timepoints, and the nature of PEs
from ages 12 to 18 was determined as persistent (present
at both timepoints), remitted (present at 12 but not 18),
emergent (present at 18 but not 12), and none (no
experiences at either timepoint).
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DNA methylation
DNA samples were extracted from cord blood on
delivery, and from peripheral blood samples in childhood
(age 7) and in adolescence (age 15–17) according to
established procedures27. DNA was bisulfite-converted
using the Zymo EZ DNA MethylationTM kit (Zymo,
Irvine, CA) and then DNA methylation of over 485,000
CpG sites was quantified using the Illumina Infinium
HumanMethylation450K BeadChip assay (HM450; Illu-
mina Inc., CA). Arrays were scanned using the Illumina
iScan, and GenomeStudio (version 2011.1; Illumina Inc.)
was used to extract signal intensities and assess initial
quality review.
Pre-processing and QC procedures
HM450 detects the proportion of molecules methylated
at each CpG site on the array. For each sample, the esti-
mated methylation level at each CpG site is expressed as a
beta value (β), which is the ratio of the methylated probe
intensity to the overall intensity and ranges from 0 (no
cytosine methylation) to 1 (complete cytosine methyla-
tion). Background correction and functional normal-
isation were performed using meffil29. Samples with >10%
of sites with a detection p value >0.01 or a bead count <3
in >10% of probes were removed from further analysis.
Non-specific probes and probes on sex chromosomes
were removed30,31. Following QC procedures, data were
available for 381,871 probes. Probes were annotated using
information provided by Illumina (genome build: hg19).
Batch effects
Samples from all timepoints in ARIES were distributed
across slides using a semi-random approach, with all
samples from each individual presented on the same array
to minimise confounding by batch. Further batch vari-
ables were recorded using a purpose-built laboratory
information management system, which also recorded
QC metrics from the standard control probes on the
HM450 array. Samples failing QC (>20% probes with p ≥
0.01) were repeated and, if unsuccessful, excluded from
further analysis.
Cell heterogeneity
To account for potential differences in methylation
arising from cell composition in whole-blood samples, cell
counts were estimated using the Houseman algorithm32
and included as covariates. However, for longitudinal
analyses including data from cord blood and whole-blood
samples, analyses instead included the first 20 indepen-
dent surrogate variable components to account for both
heterogeneity between cord blood and peripheral blood
samples as well as batch effects. Previous research has
indicated that surrogate variables derived in this way
account for cell count heterogeneity as well as estimated
cell counts33,34.
Potential confounders
Pregnancy and birth-related variables were considered
as potential confounders, including parity (number of
pregnancies resulting in live birth), maternal age at child’s
birth (derived from date of birth), maternal smoking
during pregnancy (never, stopped first trimester, con-
tinued throughout pregnancy), infections during preg-
nancy (at any time), and delivery method (caesarean; yes/
no). Factors relating to the child included gender, smok-
ing, and use of psychiatric medications. Data concerning
child smoking behaviour during adolescence were not
available for all samples; therefore, a proxy smoking
variable was derived using DNAm signals from probes
previously associated with smoking35,36. This method has
been shown to distinguish between smokers and non-
smokers (e.g. see 20). One child reported use of psychiatric
medications across the study period and was removed
from the analysis sample.
Statistical analyses
We investigated the association between DNAm and
PEs in four stages. All analyses were conducted using R
(version 3.3.1) unless otherwise stated.
Epigenome-wide Association Study
The Epigenome-wide Association Study (EWAS) func-
tion in meffil29 was used to conduct six epigenome-wide
association studies of PEs at ages 12 and 18 with cord
blood, age-7 peripheral blood, and age-15/17 peripheral
blood DNAm. Parity, maternal age, maternal smoking
during pregnancy, infections during pregnancy, delivery
methods, and child’s gender were included as covariates,
as well as estimated cell counts. Analyses using DNAm
data from age 7 or age 15–17 also included child age as a
covariate. Probes with values at the extremes of the dis-
tribution (5%) were winsorised. Statistical significance was
determined using a Bonferroni correction, giving a
threshold of p < 1.3 × 10−7. Tests with p < 5 × 10−5 were
defined as reaching suggestive significance.
Continuity of PEs across adolescence
The CpG sites most strongly associated with PEs at
either timepoint (12 or 18, p < 5 × 10−5) were assessed for
association with the continuity of PEs between 12 and 18
(persistent, remitted, emergent, none) using ANOVA.
Post hoc tests were used to determine the relationships
between groups. Significant results (p < 0.00045; p= 0.05/
110 CpG sites) were re-run with linear models to include
all previously described covariates.
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Longitudinal DNAm trajectories and continuity of PEs
Multilevel models were constructed to test the asso-
ciation between the methylomic trajectories of the top
CpG sites and the continuity of PEs across adolescence,
where DNAm was the dependent variable. A linear spline
term with a knot at 7 was included to allow for different
linear changes from 0 to 7 and from 7 to 15–17. Models
were also adjusted for all previously described pregnancy
and birth-related covariates, and the first 20 independent
surrogate variable components to account for hetero-
geneity between cord blood and peripheral blood samples
(e.g. cell composition and batch effects). Models were
repeated including derived smoking scores as previously
described.
Differentially methylated regions
The comb-p module in Python was used to identify
DMRs by combining spatially correlated p values from
each EWAS. We used a seed p value of <0.001, a max-
imum distance of 500 bp, and a minimum of three probes.
Statistical significance was determined using a Šidák
correction for multiple testing, where p < 0.05 is
significant.
Gene Ontology (GO) enrichment analysis
Enrichment analyses were conducted to assess the over-
representation of GO37 biological processes and functions
in CpG sites of each EWAS where p < 0.001. A lenient
significance threshold was used to maximise our probes of
interest. We used a methodology that controls for the
number of probes that are annotated to each gene, as well
as taking into account the hierarchical structure of
ontological categories by grouping terms where the sig-
nificant enrichment was explained by the overlap with a
more significant term (as described in ref. 20).
Replication
CpG sites of interest (detailed below) were tested for
association with PEs in the Environmental Risk (E-Risk)
Longitudinal Twin Study, a nationally representative
cohort of 2232 British-born twins, which has been pre-
viously described in detail38. In this sample, DNAm from
whole-blood samples obtained at age 18 was also quan-
tified using the Illumina Infinium HumanMethyla-
tion450K BeadChip assay (HM450; Illumina Inc., CA)39,
and PEs between 12 and 18 years were obtained from an
interview that is similar to the PLIKSi40. Following strin-
gent quality control procedures using the wateRmelon
package41, data were available for 1658 individuals at age
18. The associations between DNAm at our CpG sites of
interest and concurrent PEs at age 18 were tested using
linear regression, controlling for gender, zygosity, batch,
and cell counts (determined using the Houseman
algorithm as previously described). Clustered standard
errors were used to calculate p values to account for the
effect of family, and were implemented using the plm
package42. For the closest consistency between timepoints
in the two studies, CpG sites associated with PEs at age 18
(p < 5 × 10−5) in the age 15–17 DNAm data from
ALSPAC were tested in the E-Risk sample. Consistently
detected CpG sites, that is, those detected in the top 100
most significant results of more than one EWAS in
ALSPAC, were also tested in the E-Risk sample.
Results
Sample characteristics
DNAm data were available on 901 samples from cord
blood, 966 at age 7, and 966 at age 15–17 (n= 845 with all
three). In those with at least one DNA sample (n= 999),
978 had PE data available for at least one timepoint (age
12: n= 929; age 18: n= 816). At age 12, 12.5% (n= 116)
reported PEs. At age 18, 8.8% (n= 72) reported PEs. In
total, 767 individuals had DNAm and PE data available for
all timepoints. Of those, 81.4% had no PEs at either
timepoint; 10.2% had PEs that remitted between 12 and
18; 6.2% had PEs that emerged between 12 and 18; and
2.2% had PEs that were persistent between 12 and 18.
Sample characteristics are displayed in Table 1.
DNAm and PEs—overview
Differences in DNAm at birth, age 7, and ages 15–17
between those with and without PEs at ages 12 and 18 did
not survive correction for multiple testing (p < 1.3 × 10−7;
reflecting 381,871 sites in each analysis). However, a
number of methylation probes were nominally significant
in each analysis (p < 5 × 10−5, detailed in the Supple-
mentary Information). The top 20 differentially methy-
lated positions (DMPs) for each analysis are detailed in
Table 2a–f, with a more extensive list provided in Sup-
plementary Tables (top 100 DMPs: Tables S1–S6).
Comparison of the top 100 DMPs across analyses showed
three CpG sites (cg16459265, cg24940155, cg25184754)
detected in more than one analysis and with the same
direction of effect, and nine genes that were detected in
more than one analysis but with different CpG sites
(Supplementary Table S7).
Cord blood DNAm and PEs
Analysis of cord blood DNAm identified seven nomin-
ally significant CpG sites associated with age-12 PEs
(Table 2a), and five with age-18 PEs (Table 2b). The top
CpG site at age 12 was cg20862283 (p= 8.66 × 10-6),
which was not mapped to a RefSeq gene. GO enrichment
analysis of the CpG sites where p < 0.001 from analysis of
PEs at age 12 identified 104 groups of related GO cate-
gories (p < 0.05, Table S8). At age 18, the top CpG site was
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cg00407329 (p= 1.84 × 10−5), which was annotated with
the gene SIM1. Fifty-one groups of GO enrichment terms
were identified (Table S9). Ranked highly among the
grouped terms were “Wnt-activated receptor activity” and
“central nervous system neuron development”. The top-
ranked terms did not show any similarities between
timepoints.
Age-7 DNAm and PEs
Analysis of age-7 DNAm identified 63 nominally sig-
nificant CpG sites associated with age-12 PEs (Table 2c),
and 19 with age-18 PEs (Table 2d). At age 12, the top CpG
site was cg22499215 (p= 2.97 × 10−7), which was not
annotated with a RefSeq gene. In the top CpG sites, 92
groups of GO terms were identified (Table S10), including
a number of terms related to brain development and “Wnt
signalling pathway”. At age 18, the top CpG site was
cg00995854 (p= 2.74 × 10−6, CD5L). In GO enrichment
analysis, 137 groups of terms were identified (Table S11).
The top-ranked term was “proteoglycan binding”,
including a number of terms related to immune processes,
as well as “neurogenesis” and terms representing neuron
development and projection. The top-ranked terms did
not show any similarities between timepoints.
Age-15–17 DNAm and PEs
Analysis of age-15–17 DNAm identified ten nominally
significant CpG sites associated with age-12 PEs (Table
2e), and six with age-18 PEs (Table 2f). At age 12, the top
CpG site was cg14284469 (p= 1.87 × 10−6, STMN2), and
114 grouped GO terms were identified (Table S12). At age
18, the top CpG site was cg25975712 (p= 1.13 × 10−5,
FAM19A5), and 123 grouped GO terms were identified
(Table S13). The top-ranked term was “rostrocaudal
neural tube patterning”, which largely included terms
related to neuronal and physical development and mor-
phogenesis. Also within the top grouped terms were
“behavioural fear response” and “behavioural defense
response”. The top-ranked terms did not show any simi-
larities between timepoints.
DNAm from cord blood, at age 7, and at ages 15–17 and
continuity of PEs between ages 12 and 18
Next, we tested the association between timepoint-
specific DNAm and continuity of PEs across adolescence
for each of the top CpG sites in each EWAS (p < 5 × 10−5).
Results for these analyses are provided in the Supple-
mentary Information, Table S14. Different patterns of
DNAm at each timepoint were observed in relation to PE
continuity. At some CpG sites, statistical differences
Table 1 Sample descriptives
DNA methylation from cord blood DNA methylation at age 7 DNA methylation at age 17
PEs at age 12 (n) 833 900 899
PEs at age 18 (n) 739 791 787
Characteristic n % (missing n)
PEs at age 12 116 12.5 69
PEs at age 18 72 8.8 182
Parity 35
0 451 46.8
1 358 37.2
2 117 12.1
3 37 3.8
Maternal age Mean= 29.5 sd= 4.4 6
Maternal smoking 18
Never 847 86.4
Stopped during pregnancy 36 3.7
Continued throughout pregnancy 97 9.9
Infections during pregnancy 445 44.6
Caesarean section delivery 92 9.6 40
Sex (male) 485 48.6
PEs psychotic experiences
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between the groups were limited to one group (e.g.
cg18752363, Fig. 1a). At other CpG sites, individuals
whose PEs had remitted by age 18 had DNAm profiles
more similar to those who never had any PEs, whereas
those with persistent PEs tended to show the greatest
differences in DNAm profiles, while those whose PEs
emerged between 12 and 18 often had intermediary dif-
ferences between the none/remitted groups and the
Table 2a Cord blood methylation and age-12 psychotic
experiences: top 20 probes
Probe p value t statistic Chromosome Annotated gene
cg20862283 8.66E-06 4.48 chr2
cg10490202 1.21E-05 −4.4 chr17 RPTOR
cg21040096 2.15E-05 4.27 chr17 RPH3AL
cg18752363 2.21E-05 −4.27 chr4 C4orf10;NOP14
cg11271415 3.15E-05 4.19 chr8 FBXO32
cg20083186 4.06E-05 4.13 chr3
cg00712792 4.28E-05 −4.11 chr16 SPIRE2
cg11936556 5.14E-05 4.07 chr5
cg14892222 5.15E-05 4.07 chr15 GOLGA8A
cg26672652 5.25E-05 4.07 chr8 PXDNL
cg13751188 5.26E-05 −4.07 chr11 TECTA
cg14829814 5.39E-05 4.06 chr12
cg26302009 6.39E-05 4.02 chr6 PHACTR1
cg01840115 6.94E-05 −4 chr13
cg06893379 7.29E-05 3.99 chr5
cg04409048 7.41E-05 3.98 chr6
cg08105378 7.57E-05 −3.98 chr19 HOMER3
cg07438586 7.92E-05 −3.97 chr6 GNL1
cg04114269 8.76E-05 −3.94 chr3 C3orf26;FILIP1L;
MIR548G
Italic rows indicate p < 5 × 10−5
Table 2b Cord blood methylation and age-18 psychotic
experiences: top 20 probes
Probe p value t statistic Chromosome Annotated gene
cg00407329 1.84E-05 4.31 chr6 SIM1
cg17972930 2.76E-05 4.22 chr15 USP50
cg07571954 3.22E-05 −4.18 chr10 C10orf131
cg05138918 4.56E-05 −4.1 chr3
cg17843418 4.64E-05 −4.1 chr17 TBC1D16
cg21167905 8.29E-05 3.96 chr1 C1orf9
cg09825080 8.67E-05 −3.95 chr16
cg02424103 9.58E-05 3.92 chr3
cg16426764 0.0001 −3.9 chr10 LHPP
cg00680277 0.00012 3.87 chr2 TTC15
cg23463608 0.00012 −3.86 chr19 GNG7
cg25930186 0.00012 −3.86 chr20 MOCS3;DPM1
cg01395281 0.00013 −3.86 chr1 ZNF593
cg25275750 0.00015 3.82 chr13 TBC1D4
cg16327647 0.00016 −3.8 chr1 CENPF
cg01496136 0.00017 −3.78 chr16
cg09568647 0.00017 −3.77 chr5
cg22694818 0.00018 3.77 chr1 LHX8
cg06475223 0.00018 −3.76 chr18 LAMA3
cg12859112 0.00019 3.76 chr6 TMEM14B
Italic rows indicate p < 5 × 10−5
Table 2c Age-7 methylation and age-12 psychotic
experiences: top 20 probes
Probe p value t statistic Chromosome Annotated gene
cg22499215 2.97E-07 −5.16 chr22
cg14263553 1.12E-06 −4.9 chr8
cg07366553 2.35E-06 −4.75 chr22 SELO
cg09553452 2.75E-06 −4.72 chr16 CDH5
cg02284814 4.82E-06 −4.6 chr1 PPP1R12B
cg17160666 4.95E-06 −4.6 chr10
cg17139666 5.04E-06 4.59 chr4
cg08032135 5.08E-06 4.59 chr8 NRG1
cg04584761 1.00E-05 −4.56 chr2 SUPT7L
cg10756647 1.00E-05 4.55 chr7 PSPH
cg16451872 1.00E-05 4.54 chr15 UBE3A
cg10725301 1.00E-05 −4.52 chr6 ZKSCAN3
cg18477816 1.00E-05 −4.52 chr11 IRF7
cg10143301 1.00E-05 4.51 chr5 TXNDC15
cg02572956 1.00E-05 −4.48 chr7 CHPF2;MIR671
cg01040786 1.00E-05 −4.41 chr5
cg02975060 1.00E-05 −4.4 chr14 MIR1185-2
cg23658045 1.00E-05 4.4 chr12 DCTN2
cg10151454 1.00E-05 −4.36 chr10 EBF3
cg10303842 2.00E-05 4.35 chr5 CDH12
Italic rows indicate p < 5 × 10−5
Table 2d Age-7 methylation and age-18 psychotic
experiences: top 20 probes
Probe p value t statistic Chromosome Annotated gene
cg00995854 2.74E-06 −4.72 chr1 CD5L
cg13845105 3.08E-06 −4.7 chr12 RPL6
cg27190398 8.76E-06 −4.48 chr16 STUB1;JMJD8
cg07143863 9.18E-06 −4.47 chr12
cg10468951 1.33E-05 −4.38 chr3 C3orf45
cg05927274 1.79E-05 −4.32 chr1
cg09936919 1.90E-05 −4.3 chr2
cg15129144 1.95E-05 −4.3 chr2 EPAS1
cg03332469 2.00E-05 4.28 chr7
cg02743632 2.00E-05 −4.28 chr1 HLX
cg20477259 2.00E-05 −4.25 chr6 TNF
cg24110396 3.00E-05 −4.22 chr10 CCNY
cg27185423 3.00E-05 −4.21 chr15
cg08522143 3.00E-05 −4.19 chr19 ZNF14
cg04936274 3.00E-05 −4.18 chr10
cg14468692 3.00E-05 −4.18 chr11 RNH1
cg15031103 4.00E-05 −4.15 chr10 LRRC27
cg05072413 4.00E-05 −4.11 chr22 FAM19A5
cg16459265 4.00E-05 −4.11 chr7 C7orf40;SNORA9
cg02108135 5.00E-05 −4.06 chr17
Italic rows indicate p < 5 × 10−5
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persistent group (e.g. cg16459265, Fig. 1d; full statistical
results reported in Table S14, Fig. 1a–f).
Longitudinal DNAm changes and continuity of PEs
We tested the association between longitudinal DNAm
and continuity of PEs between 12 and 18 for the pre-
viously identified top CpG sites. Results are provided in
Supplementary Table 15 for the full longitudinal model.
Longitudinal models were unaffected by the inclusion of a
DNAm-derived smoking score. For several CpG sites, the
methylation trajectory was nominally different between
groups (remitted, emergent, or persistent PEs—examples
are given in Fig. 2).
Differentially methylated regions
We tested for DMRs using the comb-p algorithm. Sig-
nificant DMRs (Šidák corrected p < 0.05) were detected at
all timepoints, and are detailed in the Supplementary
Information (Table S16). Nine DMRs were identified in
cord blood associated with age-12 PEs; four with age-18
PEs. Thirty-five DMRs were identified in age-7 samples
associated with age-12 PEs, 11 with age-18 PEs. Fourteen
DMRs were identified in age 15–17 samples associated
with age-12 PEs, 11 with age-18 PEs. Of note, six regions
were differentially methylation in association with either
age-12 or age-18 PEs in both age-7 and age
15–17 samples, spanning regions including HLA-DPB2
and HIVEP3 (associated with age-12 PEs), and GDF7 (age-
18 PEs). A full list of significant DMRs at each timepoint
is available in the Supplementary Information, Table S16.
Replication
No associations between DNAm at age 15–17 and PEs
at age 18 in the ALSPAC sample were replicated in the E-
Risk sample (all p’s > 0.05). However, DNAm at the CpG
site cg16459265 (consistently detected among the top 100
CpG sites in the ALSPAC sample across the different
ages) was found to be associated with age-18 PEs in the E-
Risk sample. At this probe, individuals with any PEs at age
18 had marginally lower DNAm than those without PEs
(difference=−0.76%, p= 0.0029) in keeping with the
hypomethylation found in the ALSPAC sample.
Discussion
Summary
This study utilised longitudinal data in a large, population-
based sample to investigate the association between
epigenome-wide DNAm patterns and the emergence and
persistence of PEs in childhood and adolescence. While no
CpG sites reached Bonferroni-corrected significance in this
study, a number of CpG sites and genes in biological
pathways relevant to psychosis appeared highly ranked in
these analyses. Genes detected in the top 100 CpG sites of
more than one analysis (though not with the same CpG site)
Table 2e Age 15–17 methylation and age-12 psychotic
experiences: top 20 probes
Probe p value t statistic Chromosome Annotated gene
cg14284469 1.87E-06 4.8 chr8 STMN2
cg00956759 2.94E-06 −4.71 chr17
cg12009697 4.13E-06 −4.63 chr2
cg21602768 8.15E-06 −4.49 chr20 ABHD12
cg17027353 1.25E-05 4.39 chr6
cg14386808 1.34E-05 −4.38 chr8
cg22035229 1.77E-05 −4.32 chr1 MSH4
cg16817992 2.11E-05 4.28 chr7 KCNH2
cg25344401 3.26E-05 4.18 chr7 FOXK1
cg05942128 4.71E-05 4.09 chr2 HOXD11
cg26370729 5.19E-05 4.07 chr5 F2RL1
cg25024734 5.84E-05 4.04 chr10
cg03945301 6.32E-05 −4.02 chr6 EHMT2
cg17103467 7.84E-05 −3.97 chr1 WDR8
cg24695977 7.92E-05 3.97 chr1
cg04554240 8.12E-05 −3.96 chr3 ESYT3
cg08621773 1.02E-04 −3.9 chr2
cg27280332 1.04E-04 −3.9 chr12
cg25827710 0.00011 −3.88 chr13 LCP1
cg15318176 0.00012 −3.86 chr7 PTPRN2
Italic rows indicate p < 5 × 10−5
Table 2f Age 15–17 methylation and age-18 psychotic
experiences: top 20 probes
Probe p value t statistic Chromosome Annotated
gene
cg25975712 1.13E-05 4.42 chr22 FAM19A5
cg24177611 1.15E-05 −4.42 chr10 KNDC1
cg25324164 1.57E-05 −4.35 chr11 FADS2
cg15986671 4.00E-05 −4.13 chr7
cg16073378 4.74E-05 4.09 chr2
cg04942547 4.82E-05 −4.09 chr20 ZFP64
cg11333576 5.26E-05 −4.07 chr19 SHC2
cg16459265 5.51E-05 −4.06 chr7 C7orf40;
SNORA9
cg09222367 7.68E-05 −3.98 chr15 IQGAP1
cg23415756 1.02E-04 3.91 chr17 NTN1
cg18656829 1.14E-04 3.88 chr13
cg06046431 1.15E-04 3.88 chr11 BDNF
cg16791444 1.17E-04 −3.87 chr17
cg11604728 1.17E-04 −3.87 chr7 POU6F2;
POU6F2
cg22012759 1.19E-04 −3.87 chr1
cg19052355 1.25E-04 3.86 chr2 GBX2
cg05580655 1.30E-04 3.85 chr3 SCHIP1
cg16740157 1.43E-04 −3.82 chr6
cg26530497 0.000156178 −3.8 chr13 SOHLH2
cg19769301 0.000156717 3.8 chr1
Italic rows indicate p < 5 × 10−5
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included BAIAP2, FGFR3 and MAD1L1, and genetic
mutations in these genes have previously been implicated in
susceptibility to psychotic disorders43–45. Also consistently
detected were LFNG and LRP5, part of the Notch and Wnt
signalling pathways (respectively), which have been reported
in previous studies of psychiatric phenotypes including
schizophrenia46,47. None of the individual CpG sites asso-
ciated with PEs at age 18 in the ALSPAC sample were
replicated in the independent E-Risk sample. Nonetheless,
attempts to replicate these results should be undertaken in
other large population-based longitudinal samples. Using a
DMR approach, six regions associated with PEs were
A B C
D E F
Fig. 1 a–f DNA methylation and the continuity of psychotic experiences (PEs) between ages 12 and 18. Boxplots represent the most strongly
associated CpG site (tested using ANOVA) at each timepoint. a DNA methylation from cord blood, CpG site detected at age 12; b DNA methylation
from cord blood, CpG site detected at age 18; c DNA methylation at age 7, CpG site detected at age 12; d DNA methylation at age 7, CpG site
detected at age 18; e DNA methylation at age 15–17, CpG site detected at age 12; f DNA methylation at age 15–17, CpG site detected at age 18. For
each boxplot, 0= never had PEs, 1= PEs remitted between 12 and 18, 2= PEs emerged between 12 and 18, and 3= PEs persisted between 12 and
18 years. Circles represent group means. PLIKSi Psychosis-like symptoms semi-structured interview
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detected consistently in both age-7 and age 15–17 samples.
The top DMR associated with age-12 PEs at age 7 (and also
significant at age 15–17) spanned 18 probes in the HLA-
DPB2, part of the major histocompatibility complex on
chromosome 6, which has been widely implicated in schi-
zophrenia48. The top DMR associated with age-18 PEs in
age-7 samples overlapped substantially with the top DMR in
age 15–17 samples, spanning 7–9 probes on chromosome 2
at exon 2 of the GDF7 gene. DNAm at this gene has pre-
viously been associated with early age of onset in anorexia
nervosa49 and is thought to play a role in nervous system
development.
The top CpG sites identified showed interesting pat-
terns of change in DNAm across development according
to the continuity of PEs across adolescence. Some CpG
sites distinguished individuals whose PEs remitted or
never had PEs from those whose experiences persisted
across or emerged during adolescence. An example is
CpG site cg16459265 (annotated to the RefSeq genes
C7orf40;SNORA9), a top CpG site associated with age-18
PEs in DNA samples from both childhood (age 7) and
adolescence (ages 15–17). Lower DNAm at this CpG site
was also associated with PEs at age 18 in the E-Risk
sample. Similarly, at the CpG site cg25975712
(FAM19A5), DNAm patterns diverged during childhood
according to PE status, but by adolescence, those whose
PEs remitted had DNAm profiles more similar to those
with no PEs (though it should be noted that DNAm is
generally low at this CpG site).
Comparison to the literature
Two studies have previously investigated the association
between DNAm and subclinical psychotic phenomena.
However, there are some differences in the study design
between the current study and this previous research. We
utilised DNAm from birth to adolescence in a large,
population-based, unrelated sample, whereas earlier stu-
dies were conducted in smaller samples of monozygotic
twin pairs discordant for childhood psychotic symptoms23
or examined conversion to psychosis in ultra-high risk,
help-seeking individuals24. Study participants also differed
in age at sample collection (ages 5 and 10 in ref. 23; age
16–30 in ref. 24) and sample type (buccal swabs in ref. 23).
The differences in time periods are an important con-
sideration when comparing these studies, as there is little
concurrence. The current study considers a broad span of
ages, compared to shorter intervals or more specific
timepoints reported in the previous reports. While the
ages included in this study cover important timepoints
developmentally, it is not possible to accurately infer what
is happening in the intervening years, or identify changes
in DNAm accompanying the specific period that the PEs
were measured. As such, it is perhaps unsurprising that
none of the CpG site associations detected here are seen
in either previous study. Furthermore, we do not have
information regarding psychotic phenomena in the years
following those included in this study. Nevertheless,
associations linked to a small number of genes are
observed across the studies. One example is the gene
PTPRN2, which is thought to be necessary for normal
neurotransmitter activity in the brain. Of note, the DMR
located on chromosome 6 (and annotated to the gene
HLA-DPB2) which was associated with age-12 PEs in our
study substantially overlaps with a similar DMR detected
in prefrontal cortex samples associated with polygenic risk
for schizophrenia50. Taken together, these studies provide
tentative early evidence for potential methylomic changes
accompanying the development of early psychosis-related
phenomena, albeit with some inconsistency regarding the
location of these changes.
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Fig. 2 a, b DNA methylation trajectories by PLIKSi psychotic
experiences (PEs) group: 0= no PEs at either timepoint; 1= PEs at age
12 that remitted by age 18; 2= no PEs at age 12 but emerged by age
18; 3= PEs that persisted from age 12 to age 18. a cg16459265
methylation and PEs. b cg25975712 methylation and PEs. Lines
represent mean DNA methylation per sample timepoint; bars
represent standard errors. PLIKSi Psychosis-like symptoms semi-
structured interview
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Methodological considerations
This study has a number of strengths. Analyses were
conducted in the relatively large ARIES sample drawn
from a population-based cohort study, with DNAm pro-
filed at multiple timepoints across early development and
PEs assessed in childhood and adolescence. Prospective
collection of high-quality phenotypic data in this cohort
allowed for investigation of the temporal relationship
between DNAm and PEs and repeated assessments
enabled investigation of trajectories of methylation and
continuity of PEs. Extensive data regarding potential
confounding factors were also available and included in
the analyses. Furthermore, this is the largest study to date
to examine the association between DNAm and pre-
clinical PEs. Research investigating DNAm in psychotic
disorders is typically performed in adult samples, where
the confounding effects of medication use are difficult to
avoid. As ARIES is a young, population-based sample,
only one participant was using psychiatric medication
(and was excluded from these analyses). Additionally, the
longitudinal investigation of early pre-clinical psychotic
experiences is particularly important to better understand
biological factors associated with the aetiology of psy-
chotic and other psychiatric disorders and facilitate early
identification of those at risk.
However, there are methodological factors that should
be taken into consideration when interpreting these
results. Firstly, DNAm data were generated from periph-
eral samples (cord blood and whole blood). This approach
is necessary when conducting research in large long-
itudinal samples (i.e. with live participants), where the
most relevant tissue (brain) is not available. Previous
research has demonstrated tissue specificity in DNAm
patterns51, limiting the conclusions that can be drawn
from studies performed in blood. However, comparison of
DNAm from blood and brain samples is possible in
reference datasets. For example, for the CpG site
cg16459265, although DNAm in blood samples is lower
and shows more variation than in brain tissue, DNAm in
blood is strongly correlated with DNAm in matched
samples of prefrontal cortex, entorhinal cortex, superior
temporal gyrus, and cerebellum52. Nevertheless, for an
epigenetic factor to have utility as a biomarker or to
facilitate early intervention, it must be detectable in per-
ipheral samples. Secondly, despite the size and high
longitudinal retention of the ARIES subsample (n~1000),
numbers in the current analyses were reduced by the
availability of both biological and phenotypic data. Pre-
vious research in ALSPAC has demonstrated non-random
attrition, whereby participants with higher polygenic risk
scores for schizophrenia were less likely to complete
questionnaires and attend data collection sessions53,
which may have reduced the power to detect factors
associated with psychosis-related phenotypes in this
study. Thirdly, it is difficult to identify the biological
plausibility of these results, especially given the small
differences detected which may represent technical arte-
facts rather than variation attributable to differences in
PEs. However, given the focus here on pre-clinical
symptoms of a complex psychiatric phenotype, it is to
be expected that relatively small differences in DNAm
would be observed, likely reflecting many genes of small
effect. In addition, the scale of genome-wide epigenetic
profiling techniques means that stringent multiple testing
correction is required when interpreting the results. In
this study, no CpG site in the EWAS analyses reached
Bonferroni-corrected levels of significance. However, we
were able to replicate one association (cg16459265) in an
independent sample and observed effects in related gene
sets such as PTPRN2 and HLA-DPB2 in other studies.
DNAm profiles across the array are not independent, and
therefore adherence to strict multiple-testing thresholds,
particularly in complex phenotypes, may lead to dis-
regarding potentially interesting findings. Finally, only one
of the CpG sites associated with PEs in the ALSPAC
sample was replicated in the independent E-Risk sample.
However, this may be due to methodological differences
in the samples, such as the differences in timings between
DNA sample collection and the data collection for PEs
(DNA sample collection preceded the measurement of
PEs in ALSPAC; in E-Risk they were collected
concurrently).
Conclusions
In conclusion, we found that DNAm across childhood
and adolescence may be associated with the emergence
and continuity of PEs between the ages of 12 and 18.
Previous research has identified epigenetic patterns rela-
ted to clinical diagnoses of psychotic disorders15–22,
although to date very few have focussed on pre-clinical
symptoms23,24 and thus the current findings substantially
extend this literature. Research uncovering early bio-
markers associated with PEs is important as it may, in the
future, have the potential to facilitate early identification
of individuals at increased risk of a range of mental health
problems, and facilitate targeting of preventive interven-
tions. Considered together with previous research, our
findings provide tentative evidence for potential methy-
lomic changes across timepoints spanning the develop-
ment of early psychotic phenomena.
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